Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care therapies. METHODS: In this phase 3, open-label, randomized trial, we evaluated belantamab mafodotin, bortezomib, and dexamethasone (BVd), as compared with daratumumab, bortezomib, and dexamethasone (DVd), in patients who had progression of multiple myeloma after at least one line of therapy. The primary end point was progression-free survival. Key secondary end points were overall survival, response duration, and minimal residual disease (MRD)-negative status. RESULTS: In total, 494 patients were randomly assigned to receive BVd (243 patients) or DVd (251 patients). At a median follow-up of 28.2 months (range, 0.1 to 40.0), median progression-free survival was 36.6 months (95% confidence interval [CI], 28.4 to not reached) in the BVd group and 13.4 months (95% CI, 11.1 to 17.5) in the DVd group (hazard ratio for disease progression or death, 0.41; 95% CI, 0.31 to 0.53; P<0.001). Overall survival at 18 months was 84% in the BVd group and 73% in the DVd group. An analysis of the restricted mean response duration favored BVd over DVd (P<0.001). A complete response or better plus MRD-negative status occurred in 25% of the patients in the BVd group and 10% of those in the DVd group. Grade 3 or higher adverse events occurred in 95% of the patients in the BVd group and 78% of those in the DVd group. Ocular events were more common in the BVd group than in the DVd group (79% vs. 29%); such events were managed with dose modifications, and events of worsening visual acuity mostly resolved. CONCLUSIONS: As compared with DVd therapy, BVd therapy conferred a significant benefit with respect to progression-free survival among patients who had relapsed or refractory multiple myeloma after at least one line of therapy. Most patients had grade 3 or higher adverse events. (Funded by GSK; DREAMM-7 ClinicalTrials.gov number, NCT04246047; EudraCT number, 2018-003993-29.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two recent phase III studies have shown significant benefit with belantamab (Table 9), and hence it is likely the drug will be reapproved in the near future with better recommendations for dosing and dose frequency.162,163”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [162]
In the citing paper
“The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [28]
In the citing paper
“Although grade ≥3 infections have been reported in up to half of patients receiving belantamab mafodotin, along with high incidences of ocular toxicity, regular ophthalmic monitoring, dose modifications, and supportive care can inform management decisions.26,28”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [28]
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationMoreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 967
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303379 · Cited by 827
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationTefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A. M., Rodeghiero, F., Randi, M. L., Vaidya, R., Cazzola, M., Rambaldi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.163 · Cited by 700
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312054 · Cited by 599
Self-citationTai, Y.-T., Mayes, P. A., Acharya, C., Zhong, M. Y., Cea, M., Cagnetta, A., Craigen, J., Yates, J., Gliddon, L., Fieles, W., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535088 · Cited by 484
Mateos, M.-V., Cavo, M., Blade, J., Dimopoulos, M. A., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(19)32956-3 · Cited by 444
Self-citationNajean, Y., & Rain, J.-D. (1997) · Blood · doi:10.1182/blood.v90.9.3370 · Cited by 297
Björkholm, M., Derolf, Å. R., Hultcrantz, M., Kristinsson, S. Y., Ekstrand, C., Goldin, L. R., Andreasson, B., Birgegård, G., Linder, O., Malm, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7542 · Cited by 245
Cited by
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Dimopoulos, M. A., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M.-V., Zweegman, S., Cook, G., Engelhardt, M., Delforge, M., Hajek, R., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01041-x · Cited by 165
“Of note, 33% and 0% of patients in the BelaVd group had lenalidomide-refractory and daratumumab-refractory disease, respectively 94,95 .”
Self-citationBelantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
Dimopoulos, M. A., Beksac, M., Pour, L., Delimpasi, S., Vorobyev, V., Quach, H., Spicka, I., Radocha, J., Robak, P., Kim, K., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403407 · Cited by 189
Self-citationTeclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2514663 · Cited by 119
“…of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations; 5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups.”
InfluentialSelf-citationCosta, L. J., Banerjee, R. K., Mian, H. S., Weisel, K. C., Bal, S., Derman, B. A., Htut, M. M., Nagarajan, C., Rodriguez, C., Richter, J. R., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02482-6 · Cited by 101
“However, based on superior PFS with belamaf-based triplet regimens in the DREAMM-7 and DREAMM-8 trials compared to approved triplets [30, 31], it is expected that belamaf will become available in more countries in coming years.”
Self-citationEinsele, H., San‐Miguel, J., Dhakal, B., Touzeau, C., Leleu, X. P., van de Donk, N. W. C. J., Sidana, S., Oriol, A., Cohen, Y. C., Harrison, S. J., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00653-9 · Cited by 70
Self-citationNeri, P., Leblay, N., Lee, H., Gullà, A., Bahlis, N. J., & Anderson, K. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00913-y · Cited by 41
Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Hájek, R., Kim, K., Grosicki, S., Sia, H., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00330-4 · Cited by 35
Self-citationNtanasis‐Stathopoulos, I., Filippatos, C., Ntanasis‐Stathopoulos, A., Malandrakis, P., Kastritis, E., Tsitsilonis, O., Dimopoulos, M. A., Terpos, E., & Gavriatopoulou, M. (2025) · American Journal of Hematology · doi:10.1002/ajh.27582 · Cited by 32
Self-citationHijacking Extracellular Targeted Protein Degrader–Drug Conjugates for Enhanced Drug Delivery
Zhao, F., Wu, Y., Schaefer, K., Zhang, Y., Miao, K., Yao, Z. W., Ganjave, S. D., Kumru, K. S., Peters-Clarke, T. M., Inague, A., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c15047 · Cited by 34
van de Donk, N. W. C. J., Moreau, P., Miguel, J. F. S., Mateos, M., Dimopoulos, M. A., Zweegman, S., Gay, F., Engelhardt, M. M., Mina, R., Zamagni, E., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00117-6 · Cited by 33
“32,33 Patients might be ineligible for CAR T-cell therapy because of frailty or comorbidities, such as cardiac disease or neurological disorders.”
Self-citationTeclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
Touzeau, C., Mina, R., Quach, H., Hungria, V., Bhutani, D., Chen, W., Kumar, S. S., Chaulagain, C. P., Dimopoulos, M. A., Bahlis, N. J., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2603870 · Cited by 39
Self-citationGay, F., Marchetti, E., & Bertuglia, G. (2025) · Hematological Oncology · doi:10.1002/hon.70067 · Cited by 37
“Over the past year, two recent Phase III studies, DREAMM‐7 [74] and DREAMM‐8 [75], have shown a significant PFS benefit of belantamab in combination with either bortezomib or pomalidomide, respectively, as a second‐line or later treatment.”
Mateos, M., Trudel, S., Quach, H., Robak, P. J., Beksaç, M., Pour, L., Hus, M., Kım, K., Анатольевна, Ж. В., Delimpasi, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016949 · Cited by 24
Self-citationvan de Donk, N. W. C. J., Moreau, P., Miguel, J. F. S., Mateos, M., Dimopoulos, M. A., Zweegman, S., Gay, F., Engelhardt, M., Mina, R., Zamagni, E., et al. (2025) · HemaSphere · doi:10.1002/hem3.70260 · Cited by 26
“Because BCMA ‐ and GPRC5D ‐ directed immunotherapies are moving to earlier lines of treatment and because patients are increasingly likely to receive more than one of these novel therapies during their disease course, optimizing treatment sequencing becomes essential to enhance overall outcomes for patients with MM. K…”
InfluentialSelf-citationTalquetamab–Daratumumab in Relapsed or Refractory Myeloma
Mina, R., Beksac, M., Rodríguez‐Otero, P., Chen, W., Mateos, M., Li, J., Moreau, P., Cohen, Y. C., Min, C., Jelínek, T., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2604657 · Cited by 28
Self-citationMukhopadhyay, P., Abdullah, H. A., Opalinska, J., Paka, P., Richards, E., Weisel, K. C., Trudel, S., Mateos, M., Dimopoulos, M. A., & Lonial, S. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01212-0 · Cited by 23
“These results demonstrate a considerable depth of response that could also provide bene fi t to patients with earlier-stage MM, including those receiving fi rst-line treatment.”
InfluentialSelf-citationHartley-Brown, M. A., Weisel, K. C., Bitetti, J., Carter, J. A., McNamara, S., Purser, M. F., Palumbo, A., & Richardson, P. G. G. (2024) · British Journal of Haematology · doi:10.1111/bjh.19627 · Cited by 20
Self-citationCharacterization of Belantamab Mafodotin–Induced Corneal Changes in Patients With Multiple Myeloma
Lee, V., Hultcrantz, M. L., Petrone, S., Lewis, E., Banna, H., Lichtman, E. I., Thulasi, P., Quick, A., Jeng, B. H., Sunshine, S. B., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.1008 · Cited by 18
Self-citationPractical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events
Terpos, E., Trudel, S., Mateos, M., Alejandre‐Alba, N., Colby, K. A., Dimopoulos, M. A., Esposti, S. D., Farooq, A. V., Gavriatopoulou, M., Gay, F., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.70015 · Cited by 15
“…versus n = 251 daratumumab, bortezomib, and dexamethasone [median follow-up 28.2 months]; DREAMM-8: n = 155 belamaf in combination with pomalidomide and dexamethasone versus n = 147 poma-lidomide, bortezomib, and dexamethasone [median follow-up 22.4 versus 20.5 months, respectively]) [6, 7].”
InfluentialSelf-citationBruins, W. S. C., Smits, F., Duetz, C., Groen, K., Korst, C. L. B. M., de Jonge, A. V., Verkleij, C. P. M., Rentenaar, R., Cosovic, M., Eken, M., et al. (2025) · Blood · doi:10.1182/blood.2025028587 · Cited by 14
Koo, S., Kim, C. Y., Lim, J.-H., Lee, E., Kim, I. Y., Shin, Y. G., & Moon, H. (2025) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2025.33.e21 · Cited by 15
Novel Treatment Options for Multiple Myeloma
Portuguese, A. J., Banerjee, R. K., Chen, G. Z., Reddi, S., & Cowan, A. J. (2025) · JCO Oncology Practice · doi:10.1200/op-24-00752 · Cited by 17
Six events that shaped antibody approvals in oncology
Paul, S., & Zhou, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1533796 · Cited by 12
Update on B‐cell maturation antigen‐directed therapies in AL amyloidosis
Jamroziak, K., Zielonka, K., Khwaja, J., & Wechalekar, A. D. (2025) · British Journal of Haematology · doi:10.1111/bjh.19960 · Cited by 12
“However, results of trials combining belantamab with bortezomib 51 and poma-lidomide 52 show very promising results.”
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
Touzeau, C., Leleu, X. P., Tiab, M., Macro, M., Perrot, A., Gay, J., Chateleix, C., Moreau, S., Karlin, L., Jacquet, C., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.19978 · Cited by 13
“17,20 Cilta-cel and ide-cel demonstrated strong activity in RRMM from first or second relapse.”
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma
Mancuso, K., Barbato, S., Raimondo, F. D., Gay, F., Musto, P., Offidani, M., Petrucci, M. T., Zamagni, E., Zambello, R., & Cavo, M. (2025) · Cancers · doi:10.3390/cancers17071168 · Cited by 10
“However, final data are awaited [81,82].”
Self-citationMajor, A., Dueck, A. C., & Thanarajasingam, G. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00035-3 · Cited by 11
Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline
Hicks, L. K., Messersmith, H. J., Hadidi, S. S. A. A., Banerjee, R. K., Derman, B. A., Kumar, S. K., Wildes, T. M., Bal, S., Bhella, S., Chmielewski, C., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02587 · Cited by 17
Cheung, A., Liu, Y., Chenoweth, A. M., Montaseri, H., Esapa, B., Chudasama, V., Baker, J. R., Thurston, D. E., & Karagiannis, S. N. (2026) · Physiological Reviews · doi:10.1152/physrev.00039.2025 · Cited by 16
Engineering de novo binder CAR-T cell therapies with generative AIPreprint
Mergen, M., Abele, D., Koleci, N., Fernandez, A. S., Sugden, M., Holzleitner, N., Carr, A., Rieger, L., Leone, V., Reichert, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.25.625151 · Cited by 16
Lebel, E., Vainstein, V., Milani, P., Palladini, G. O., Shragai, T., Lavi, N., Magen, H., Assayag, M., Avivi, I. M., & Gatt, M. E. (2024) · Acta Haematologica · doi:10.1159/000541594 · Cited by 10
“The recent extensive experience with BLM in DERAMM-7 and DREAMM-8 studies in MM is supportive of general approach to corneal toxicity with BLM, but the ideal dosing approach is still under debate [12, 13].”
Self-citationPapathanasiou, T., Kaullen, J. D., Polireddy, K., Chen, X., Ho, Y. L., Taylor, A. B., Struemper, H., Carreño, F., & Ferron‐Brady, G. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01508-1 · Cited by 11
“…dexamethasone versus daratumumab with bort-ezomib and dexamethasone (hazard ratio [HR] 0.41 [95% CI 0.31–0.53]) and the DREAMM-8 (NCT04484623) trial of belantamab mafodotin with pomalidomide and dexamethasone versus pomalidomide with bortezomib and dexamethasone (HR 0.52 [95% CI 0.37–0.73]) [5, 6].”
InfluentialCani, L., Parikh, R., Joseph, N. S., Gupta, V. A., Hofmeister, C. C., Kaufman, J. L., Nooka, A. K., Lonial, S., & Mina, R. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.003 · Cited by 8
Advancements in the Treatment of Multiple Myeloma
Zavaleta‐Monestel, E., Quesada-Villaseñor, R., Barrantes-López, M., Arguedas‐Chacón, S., Campos-Hernández, J., Rojas-Chinchilla, C., García-Montero, J., Castro-Ulloa, J., Anchía-Alfaro, A., & Montenegro-Chaves, J. R. (2024) · Cureus · doi:10.7759/cureus.74970 · Cited by 12
“Below is a table demonstrating the different medications commonly used combined as a treatment for this condition (Table 2 ) [29,33,34].”
Diaz, A. A., Alouch, S. S., Chawla, Y., & Gonsalves, W. I. (2024) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s490021 · Cited by 13
Goel, U., Zanwar, S., Cowan, A. J., Banerjee, R. K., Khouri, J., & Dima, D. (2025) · Cancer Management and Research · doi:10.2147/cmar.s510408 · Cited by 8
“63,82,83 However, patients who are selected and ultimately infused with CAR T tend to have a slower disease tempo and otherwise favorable performance status, which limits direct comparisons of these trials.”
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma
van de Donk, N. W. C. J., & Zweegman, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00927-6 · Cited by 8
“Patients with disease progression while receiving lenalidomide might benefit most from BVd, with a change from an immunomodulatory drug to the proteasome inhibitor bortezomib (class switch).”
InfluentialPopat, R., Augustson, B. M., Gironella, M., Lee, C., Cannell, P., Patel, N., Kasinathan, R. S., Rogers, R., Shaikh, M., Curry, A., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01155-y · Cited by 10
“…and dexamethasone had a manageable safety pro fi le for patients with RRMM. ORR was broadly similar across cohorts, taking into consideration the different lengths of median follow-up (22.9 – 30.6 months), and was consistent with other belantamab mafodotin combination studies [4, 6, 8, 10].”
BackgroundResultInfluentialSelf-citationCurrent Treatment Strategies for Multiple Myeloma at First Relapse
Mavrothalassitis, E., Triantafyllakis, K., Malandrakis, P., Gavriatopoulou, M., Kleber, M., & Ntanasis‐Stathopoulos, I. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051655 · Cited by 7
“Overall survival at 18 months was 84% in the BVd group compared to 73% in the DVd group [38].”
Dileo, R., Mewawalla, P., Babu, K., Yin, Y., Strouse, C. S., Chen, E., Shaikh, H. G., Davis, J. A., Green, K. M., Alkharabsheh, O. A., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01226-8 · Cited by 9
“However, data from recent phase III randomized controlled trials (DREAMM-7 and DREAMM-8) [6, 7] demonstrated signi fi cant improvements in depth and duration of response with belantamab mafodotin combination therapies when compared to standard-of-care treatments for RRMM.”
Self-citationFeng, X., Yu, X., Yang, S., Yuan, G., Huang, M., He, Z., & Wu, J. (2025) · Clinical Drug Investigation · doi:10.1007/s40261-025-01447-6 · Cited by 7
Martino, E. A., Caridà, G., Lofaro, D., Bruzzese, A., Labanca, C., Mendicino, F., Lucia, E., Olivito, V., Puccio, N., Neri, A., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105514 · Cited by 7
Hungria, V., Hus, M., Fu, C., Анатольевна, Ж. В., Wård, C., Ho, P. J., Mikulski, D., Muroňová, L., Cerchione, C., Loubert, A., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00163-2 · Cited by 7
Self-citationTerpos, E., Gavriatopoulou, M., Ntanasis‐Stathopoulos, I., Malandrakis, P., Fotiou, D., Kanellias, N., Migkou, M., Theodorakakou, F., Spiliopoulou, V., Solia, E., et al. (2025) · Blood · doi:10.1182/blood.2025031629 · Cited by 7
Self-citationHu, Y., Du, X., Yuan, J., Gong, X., Zhu, Y., Li, H., Lin, X., Zheng, F., Ran, Y., Na, Z., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217685 · Cited by 9
Ntanasis‐Stathopoulos, I., Filippatos, C., Malandrakis, P., Koutoulidis, V., Trapali, M., Kastritis, E., Terpos, E., Dimopoulos, M. A., & Gavriatopoulou, M. (2025) · Leukemia · doi:10.1038/s41375-025-02677-5 · Cited by 8
Self-citationBelantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience
Hultcrantz, M. L., Derkach, A., Hassoun, H., Korde, N., Maclachlan, K. H., Mailankody, S., Patel, D., Shah, U. A., Tan, C. R. C., Chung, D. J., et al. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100103 · Cited by 18
“10,11 As clinical trials have strict inclusion/exclusion criteria, the trial population does not necessarily re fl ect the entire population of patients with relapsed/refractory multiple myeloma.”
Beksaç, M., Şahlı, E., Rabea, A. M., Saydam, G., Tombak, A., Alhuraiji, A., Mutahar, E. Y., Hosny, M., Alhejazi, A., Mattar, M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.05.019 · Cited by 6
Mewawalla, P., Dileo, R., Yin, Y., Strouse, C. S., Shaikh, H. G., Davis, J. A., Alkharabsheh, O. A., Rashid, A., Ahmed, N., Abdallah, A.-O. A., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.015 · Cited by 9
Self-citationvan Besien, H. J., Ozkan, G., Easton, N., Tix, T., Alhomoud, M., Shouval, R., Rejeski, K., & Yamshon, S. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019617 · Cited by 8
Targeted Delivery Strategies for Multiple Myeloma and Their Adverse Drug Reactions
Li, S., Wang, H., Xiong, S., Liu, J., & Sun, S. (2024) · Pharmaceuticals · doi:10.3390/ph17070832 · Cited by 9
“DREAMM-7 is a phase 3, open-label, randomized trial that evaluated the efficacy of combining belantamab mafodotin, BTZ, and dexamethasone (BVd) versus the combination of daratumumab, BTZ, and dexamethasone (DVd) in patients with refractory MM [30].”
BackgroundCurrent State of Evidence on Definitions and Management of High-Risk Multiple Myeloma
Lal, B. M., van Rhee, F., & Hadidi, S. A. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01639-5 · Cited by 8
“The PFS benefit was maintained in patients with high-risk disease (HR: 0.36, 95% CI: 0.22–0.58) [119].”
InfluentialApproaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?
Vijjhalwar, R., Kannan, A., Fuentes-Lacouture, M. C., & Ramasamy, K. (2025) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-025-02008-9 · Cited by 6
“The DREAMM-7 trial compared belantamab mafodotin, bortezomib, and dexamethasone (BVd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed MM who had received at least one prior line of therapy [65].”
InfluentialA Belantamab Mafodotin Revival in Multiple Myeloma Therapy
Trudel, S., & Stewart, A. K. (2024) · New England Journal of Medicine · doi:10.1056/nejme2406799 · Cited by 6
Yadav, R., Chaudary, J. K., Bisht, K., Dhamija, P., Chaudhary, P. K., Nath, U. K., & Jain, N. K. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152390 · Cited by 7
Shah, D., Sparano, F., Shah, V., Krepper, D., Baldi, T., Chakraborty, R., & Efficace, F. (2025) · European Journal Of Haematology · doi:10.1111/ejh.70002 · Cited by 6
Korst, C. L. B. M., Plattel, W. J., de Kort, E., Smits, F., Croockewit, A. J., Levin, M., Westerman, M., de Weerdt, O., Nijhof, I. S., Wegman, J. J., et al. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00298-4 · Cited by 7
Lal, B. M., Alzubi, M., Alrawabdeh, J. A., Shaughnessy, J. D., Zhan, F., Siegel, E. R., Schinke, C., Thanendrarajan, S., Zangari, M., van Rhee, F., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015648 · Cited by 8
Boytsov, N. N., McGuiness, C. B., Zhou, Z., Huo, T., Montgomery, K., Kotowsky, N., & Chen, C. (2025) · Future Oncology · doi:10.1080/14796694.2025.2504318 · Cited by 5
“The BCMA-targeting antibody-drug conjugate belantamab mafodotin is being evaluated in combination regimens for early LOTs and has shown progression-free survival (PFS) benefits in phase 3 RRMM studies [56,57].”
Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review
Pan, D., Kumar, A. D., Lipof, J. J., Chung, A., Wolf, J. L., Martin, T. G., Arora, S., Sayre, P. H., & Chari, A. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2511179 · Cited by 6
“…and dexamethasone in RRMM, resulting in withdrawal of FDA approval in 2022, subsequent studies of belantamab mafodotin combined with bortezomib and dexamethasone in DREAMM7 and with pomalidomide and dexamethasone in DREAMM8 have since shown clear superiority over standard-of-care triplets [69–71].”
Hungria, V., Polo, V. A., Corzo, A., Crusoé, E., Farah, M. E., Iutaka, N. A., Martınez, G., Ramírez-Alvarado, A. G., Romano-Bucay, S., Schlottmann, P. G., et al. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00354-2 · Cited by 4
Self-citationImmunotherapy in chronic lymphocytic leukemia: advances and challenges
Gao, P., Zhang, Y., Ma, J., & Zhang, Y. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00644-5 · Cited by 4
“However, it was withdrawn from the market in 2022 due to insufficient survival benefits compared to conventional therapies and the presence of fatal side effects [183].”
Moore, S. E., Miller, H., Parrish, C., Seymour, F., Miller, L. J., Chandler, T., Land, J., Karpha, I., Brearton, G., Thompson, S., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.70041 · Cited by 6
“73 However, almost all patients (96”
Hanafin, P., Ho, Y. L., Papathanasiou, T., Fulci, G., Sule, N., Kremer, B. E., & Ferron‐Brady, G. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01174-0 · Cited by 4
Guo, Y. L., Song, Y., Wang, H., Yang, L., Zhang, J., Shen, Z., Kan, W., Wang, Y., Duan, H., Geng, S., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.09.009 · Cited by 5
“…but was withdrawn in 2022 after failing to meet endpoints in its confirmatory Phase III trial 15 — 17 , achieved the primary endpoint of progression-free survival (PFS) in combination with bortezomib and dexamethasone in recent DREAMM-7 trial, raising hopes for its potential reap-proval 18,19 .”
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists
Mushtaq, A. H., Cheema, A. Y., Ali, H. M., Shatnawi, Y., Ashruf, O. S., Ahmad, E. N., Lytvynova, O., Munir, M., Asif, M. A., Ahmad, M., et al. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101339 · Cited by 5
Advances in immune microenvironment profiling during multiple myeloma progression and therapy
Bai, J., Nishimura, N., & Kawano, Y. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04110-0 · Cited by 5
“It is approved for the treatment of relapsed or refractory MM [80].”
Segers, F., & Delforge, M. (2026) · Targeted Oncology · doi:10.1007/s11523-025-01189-7 · Cited by 4
“[25].”
InfluentialGan, X., Li, L., Zhang, L., Zheng, Y., Niu, T., & Yu, Z. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01199-z · Cited by 4
Watson, E. C. R., Shuwa, H. A., Heycock, M. W. D., Wade, J., Wang, C.-Y., Htun, M., Li, L., Niehaus, V., Baker, W., Miller, B., et al. (2026) · BMJ Immunology · doi:10.1136/bmjimm-2026-000029 · Cited by 8
Mele, G., Sgherza, N., Pastore, D., & Musto, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206238 · Cited by 5
“The pivotal, randomized, phase 3 trials DREAMM-7 (NCT04246047) [23,24] [belan-tamab, bortezomib and desamethasone (BVd) vs. DaraVd] and DREAMM-8 (NCT04484623) [25] [belantamab, pomalidomide and dexamethasone (BPd) vs. PVd] investigated combinations containing the drug-conjugated, anti-BCMA…”
BackgroundMethodRodriguez, C., Rodriguez, T. E., Kentos, A., Driessen, C., Suanmi, K., Lesokhin, A. M., Yee, A. J., Minella, A. C., Maraboina, R., Upreti, V. V., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2528115 · Cited by 4
“[45,46] and grade ≥3 CRS (4–5”
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Lucijanic, M., Sabljic, A., & Krečak, I. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2410841 · Cited by 4
Rüsing, L. Z., Schweighofer, J., Aschauer, J., Jeryczynski, G., Vospernik, L., Gisslinger, H., Bumberger, A. M., Cserna, J., Riedl, J., Agis, H., et al. (2025) · Cancers · doi:10.3390/cancers17142398 · Cited by 3
“These findings align with data from DREAMM-6, ALGONQUIN, DREAMM-7, and DREAMM-8 trials, which support the use of dose modifications to improve tolerability while preserving clinical efficacy (Table 4) [11–13 , 29 ].”
Rees, M. J., Xu, T. T., Atallah‐Yunes, S. A., Lim, K. J. C., Ailawadhi, S., Parrondo, R. D., Fonseca, R., Bergsagel, P. L., Hayman, S. E., Dispenzieri, A. A., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.003 · Cited by 3
Endless possibilities and how to exploit them? What is the optimal treatment sequence?
Chakraborty, R., Bhutani, D., & Lentzsch, S. (2025) · Hematology · doi:10.1182/hematology.2025000760 · Cited by 3
Mina, R., Antonioli, E., Barilà, G., Bolli, N., Botta, C., Furlan, A., Liberatore, C., Martello, M., Móre, S. M. C., Oliva, S., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.016 · Cited by 3
Multiple myeloma in 2026 — current guidelines and new therapies
Charliński, G., Vesole, D. H., & Jurczyszyn, A. (2026) · Nowotwory Journal of Oncology · doi:10.5603/njo.108723 · Cited by 3
Kumari, S., Cool, L. M., Howard, E., & Pawar, J. S. (2026) · Cancers · doi:10.3390/cancers18132102 · Cited by 6
“It has been recently reapproved in October 2025 in combination with bortezomib and dexamethasone for relapsed refractory multiple myeloma [22].”
Costa, B. A., Costa, T. A., Chagas, G. C. L., Mouhieddine, T. H., Richter, J. R., Usmani, S. Z., Mailankody, S., Rajeeve, S., & Hashmi, H. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.09.008 · Cited by 3
Richter, J. R., Nooka, A. K., Rodríguez‐Otero, P., Schjesvold, F. H., Katodritou, E., Combe, E., Scott, M., Cooper, L., Sly, I., Ballew, N., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.27661 · Cited by 3
“In the absence of other direct randomized controlled trials (RCTs), this NMA further supports DREAMM-7 findings, with BVd exhibiting superior benefit versus DVd [8].”
InfluentialSelf-citationPatel, M. N., Locke, S. C., Falvey, C. A., Troy, J. D., Herring, K. W., Bolgioni, A. F., Elcock, C. H., Iadeluca, L. L., Chase, C. C., Gasparetto, C., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.04.008 · Cited by 5
Freidlin, B., & Korn, E. L. (2025) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2025.2482463 · Cited by 3
Singh, G., Saldaña, E. J., Spencer, J., & Bollag, R. J. (2025) · Laboratory Medicine · doi:10.1093/labmed/lmaf014 · Cited by 3
Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma
Sorgiovanni, I., Giudice, M. L. D., Galimberti, S., & Buda, G. (2025) · Pharmaceuticals · doi:10.3390/ph18020145 · Cited by 4
“Therefore, BVd therapy demonstrated a superior PFS benefit over DVd in RRMM patients, although it was associated with a higher incidence of serious adverse events, such as ocular events [70].”
Watson, E. C. R., Djebbari, F., Panitsas, F. P., Vallance, G. D., Asher, S., Saeed, M., Walker, M., Powell, M., Rampotas, A., Leary, H., et al. (2025) · eJHaem · doi:10.1002/jha2.70039 · Cited by 2
“However, belamaf, as a component of combination therapy in the DREAMM-7 and DREAMM-8 trials, showed significant PFS superiority over standard-of-care in first-or later-relapse MM [11, 12].”
Sunami, K., Fujisaki, T., Funaki, T., Ichii, M., Ito, S., Matsumoto, M., Oshima, K.-I., Suzuki, K., & Takakuwa, T. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf148 · Cited by 3
“The majority of patients treated with belantamab mafodotin in clinical trials experienced OAEs [7, 8].”
InfluentialSelf-citationJenner, M. W., Boyd, K. D., Choudhuri, S., Parrish, C., Garg, M. K., Stern, S., & the British Society of Haematology and UK Myeloma Society (2025) · British Journal of Haematology · doi:10.1111/bjh.70149 · Cited by 2
Self-citationRizzello, I., Sacchetti, I., Barbato, S., Solli, V., Stefanoni, P., Cani, L., Quaresima, M., Belotti, A., Sgherza, N., Gentile, M., et al. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01956-w · Cited by 4
“Indeed, only the registration trials of cilta-cel [17] and the combination of belan-tamab mafodotin plus pomalidomide and dexamethasone [19] included patients with these characteristics, whereas such patients were excluded from the pivotal trials evaluating BelaVd [18], SelVd [16], and PVd [13].”
InfluentialSelf-citationZhang, Y., Lei, Y., Huang, Y., Gao, Y., Liu, R., Guo, K., Zhao, C., & Lei, M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11317-1 · Cited by 2
“These findings indicate that the BVd regimen offers sig - nificantly greater clinical benefit than the DVd regimen for patients with R/R MM [ 40 ].”
Wu, Z., Lu, H., Liu, T., Yue, X., Wang, L., Ma, C., Kovarik, P., Ding, X., Wang, M., Zhang, C., et al. (2026) · Research · doi:10.34133/research.1078 · Cited by 5
“According to ClinicalTrials.gov , the number of registered clinical trials about Dex has surpassed 4,000, and the applicable field of Dex has been expanded in recent years [ 48 , 49 ], which suggested that Dex is a good alternative for developing medication.”
Newman, C., Taylor, C., Sohanpal, G., Högg, T., Kennedy, J., McKinley, E. T., Koudouna, E., Sayers, E. J., Jones, A. T., Watson, P., et al. (2026) · Cell Biology and Toxicology · doi:10.1007/s10565-026-10183-2 · Cited by 2
“Belantamab mafodotin has been evaluated as a monotherapy and in combination regimens in relapsed/refractory MM (RRMM) and is under investigation for other indications (ClinicalTrials. gov 2023; ClinicalTrials.gov 2024; Dimopoulos et al. 2024, 2023; Hungria et al. 2024).”
Zhang, H., Chen, X., Qiao, S., Meng, H., Long, H., Zhong, H., Liu, Y., Song, Y., Gao, Y., Liu, Y., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050526 · Cited by 2
“Bortezomib (BTZ, Figure 2C), a boronic acid-based dipeptide proteasome inhibitor, selectively inhibits the chymotrypsin-like activity of the mammalian 20S proteasome [9].”
Zhou, N., Li, M., Huang, Y. Q., Wang, Y., & Wang, J. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070849 · Cited by 2
“[22] https://doi.org/10.3390/pharmaceutics18070849 Low THP-1 (>80% viability) Event-driven mechanism [29,58] Abbreviations: RRMM, relapsed/refractory multiple myeloma; AML, acute myeloid leukemia; MDS, myelodysplastic syndromes; B-NHL, B-cell non-Hodgkin lymphoma; MCL, mantle cell lymphoma; BL,…”
InfluentialMoore, S. E., Cornic, L., Crossman-Barnes, C.-J., José, S., Khalaf, Z., Yong, K., Soutar, M., & Woods, P. (2024) · eJHaem · doi:10.1002/jha2.1058 · Cited by 2
Chari, A., Bal, S., Ailawadhi, S., Krishnan, A. Y., Patel, K. K., Berdeja, J. G., Garfall, A. L., Callander, N. S., Banerjee, R., Alsina, M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.03.008 · Cited by 4
Relapsed/refractory multiple myeloma: standard of care management of patients in the Gulf region
Alhuraiji, A., Farsi, K. A., Mheidly, K., Elsabah, H., Cherif, H., Hamad, A. A., Marashi, M., Al-Hateeti, H., Osman, H. Y., & Mohty, M. (2025) · Clinical Hematology International · doi:10.46989/001c.137860 · Cited by 3
Ntanasis‐Stathopoulos, I., Malandrakis, P., Filippatos, C., Maganas, S., Fotiou, D., Theodorakakou, F., Spiliopoulou, V., Kanellias, N., Migkou, M., Eleutherakis‐Papaiakovou, E., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.08.003 · Cited by 3
Self-citationYi, J. H., Yoon, D. H., & Kım, K. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.11.003 · Cited by 2
Metadata
- Authors
- Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Ribas de Almeida, A. C., Hajek, R., Kim, K., Grosicki, S., Sia, H., Bryant, A., Pitombeira de Lacerda, M., Aparecida Martinez, G., Sureda Balarí, A. M., Sandhu, I., Cerchione, C., Ganly, P., Dimopoulos, M., Fu, C., Garg, M., Abdallah, A.-O., Oriol, A., Gatt, M. E., Cavo, M., Rifkin, R., Fujisaki, T., Mielnik, M., Pirooz, N., McKeown, A., McNamara, S., Zhou, X., Nichols, M., Lewis, E., Rogers, R., Baig, H., Eccersley, L., Roy-Ghanta, S., Opalinska, J., & Mateos, M.-V.
- Affiliations
- From Clinica São Germano (V.H.) and Hospital das Clínicas and Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo (G.A.M.), São Paulo, Centro de Pesquisa e Ensino em Saúde de Santa Catarin, Florianópolis (A.C.R.A.), and Universidade da Região de Joinville and Centro de Hematologia e Oncologia, Joinville (M.P.L.) — all in Brazil; Medical University of Lodz, Lodz (P.R.), Medical University of Lublin, Lublin (M.H., M.M.), and the Medical University of Silesia, Katowice (S.G.) — all in Poland; Gorodskaya Klinicheskaya Bol’nitsa Imeni Saint Petersburg Botkina, Moscow (V.Z.); the Royal North Shore Hospital (C.W.) and Liverpool Hospital (A.B.), Sydney, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and Pindara Private Hospital, Gold Coast, QLD (H.S.) — all in Australia; the Department of Hematooncology, University Hospital Ostrava, and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic (R.H.); Sungkyunkwan University and Samsung Medical Center, ...
- Medical University of Lublin (PL)
- ORCID
- Robak, Pawel
- Hus, Marek
- Ho, P. Joy
- Grosicki, Sebastian
- Bryant, Adam
- Pitombeira de Lacerda, Marcelo
- Sandhu, Irwindeep
- Cerchione, Claudio
- Ganly, Peter
- Dimopoulos, Meletios
- Fu, Chengcheng
- Garg, Mamta
- Abdallah, Al-Ola
- Oriol, Albert
- Gatt, Moshe E.
- Rifkin, Robert
- Mielnik, Michał
- Pirooz, Nick
- McKeown, Astrid
- McNamara, Simon
- Nichols, Maureen
- Rogers, Rachel
- Eccersley, Lydia
- Mateos, María-Victoria
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-08-01
- Volume
- 391
- Issue
- 5
- Pages
- 393-407
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399257301
- Semantic Scholar
- 2132fd7eacf293858f040cac026dbc0e4e2031e8
- Cited by
- 199
- References
- 28
- Citations by year
- 2026: 83 · 2025: 96 · 2024: 20
- FWCI
- 61.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (acceptedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- belantamab mafodotin, daratumumab, bortezomib, dexamethasone, relapsed/refractory multiple myeloma, progression-free survival, overall survival, minimal residual disease, ocular adverse effects, visual acuity, combination therapy, monoclonal antibody-drug conjugate, proteasome inhibitors, immunomodulators
- MeSH terms
- Bortezomib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Survival Analysis, Neoplasm, Residual, Disease Progression, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.